Madrigal Pharmaceuticals Inc (MDGL) Stock Price, Quote & News

Company Profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 267 824 2827

Website: www.madrigalpharma.com

Address:

Four Tower Bridge, Suite 200 200 Barr Harbor Drive, West Conshohocken, United States

mdalinaqvi Jul. 16 at 10:40 PM

$MDGL

0 · Reply

scott52 Jul. 16 at 9:59 PM

$MDGL Bid this stock higher so they can partner with Viking. Fuck Big Pharma.

0 · Reply

dllydalley29 Jul. 16 at 9:02 PM

$MDGL Need to get these spammers out of here.

0 · Reply

All_just_a_game Jul. 16 at 8:43 PM

$AKRO $ALT $MDGL $VKTX lmfao 😂 The bitch in class ALT drug can’t get a partner.

1 · Reply

balzofsteel Jul. 16 at 8:17 PM

$MDGL Preparation H has “ Flushables” This is for the non believers. Just apply and flush and the pain goes away in a few days not seconds.( Big losses on them puts) Just “put “ it on and watch the results.

0 · Reply

Wallst45 Jul. 16 at 8:08 PM

$MDGL OPPENHEIMER RAISED ITS PRICE TARGET ON MADRIGAL PHARMACEUTICALS TO $500

0 · Reply

balzofsteel Jul. 16 at 8:05 PM

$MDGL what will the shorts come up with next? MDGL going to $0? Try $500 What a bunch or sore losers!

0 · Reply

jeffshow12 Jul. 16 at 7:45 PM

$MDGL "Oppenheimer aumenta preço-alvo das ações da Madrigal Pharmaceuticals após notícias de patente" https://br.investing.com/news/analyst-ratings/oppenheimer-aumenta-precoalvo-das-acoes-da-madrigal-pharmaceuticals-apos-noticias-de-patente-93CH-1611244

0 · Reply

Wallst45 Jul. 16 at 7:25 PM

$MDGL BMY or PFE

0 · Reply

balzofsteel Jul. 16 at 7:18 PM

$MDGL 2044

0 · Reply

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

Jun 20, 2025, 7:35 AM EDT - 26 days ago

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Jun 20, 2025, 6:30 AM EDT - 26 days ago

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Jun 17, 2025, 4:05 PM EDT - 4 weeks ago

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2025, 8:00 AM EDT - 6 weeks ago

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

May 17, 2025, 8:10 AM EDT - 2 months ago

In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals

May 10, 2025, 7:15 AM EDT - 2 months ago

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

May 6, 2025, 4:20 PM EDT - 2 months ago

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra

May 1, 2025, 1:01 PM EDT - 2 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

Apr 29, 2025, 8:00 AM EDT - 2 months ago

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Apr 18, 2025, 8:00 AM EDT - 3 months ago

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Apr 16, 2025, 7:00 AM EDT - 3 months ago

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.

Mar 11, 2025, 8:00 AM EDT - 4 months ago

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Feb 28, 2025, 2:29 PM EST - 4 months ago

Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)

Feb 26, 2025, 6:33 PM EST - 4 months ago

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Feb 26, 2025, 12:28 PM EST - 5 months ago

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

Feb 26, 2025, 11:41 AM EST - 5 months ago

Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook

Feb 26, 2025, 11:05 AM EST - 5 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 5 months ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 26, 2025, 6:30 AM EST - 5 months ago

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 21, 2025, 8:00 AM EST - 5 months ago

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Feb 12, 2025, 8:00 AM EST - 5 months ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Jan 29, 2025, 11:50 AM EST - 6 months ago

MoneyShow's Best Investment Ideas For 2025: Part 7

ARCC ASML HESM IMMR MARA TOST VLGEA

Jan 19, 2025, 9:30 AM EST - 6 months ago

Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH

Jan 13, 2025, 6:45 AM EST - 6 months ago

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Jan 9, 2025, 6:22 AM EST - 6 months ago

Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion

Jan 8, 2025, 11:13 AM EST - 6 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MRK PFE

Jan 3, 2025, 8:00 AM EST - 6 months ago

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 25, 2024, 8:29 AM EST - 8 months ago

Top 3 Health Care Stocks That May Dip This Month

BFLY CNMD

Nov 6, 2024, 8:00 AM EST - 9 months ago

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Nov 3, 2024, 9:00 AM EST - 9 months ago

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Oct 31, 2024, 2:50 PM EDT - 9 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 8:00 AM EDT - 9 months ago

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Oct 28, 2024, 3:42 AM EDT - 9 months ago

Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings

Oct 24, 2024, 12:11 PM EDT - 9 months ago

Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings

Oct 21, 2024, 8:00 AM EDT - 9 months ago

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

Oct 18, 2024, 8:00 AM EDT - 9 months ago

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

Oct 2, 2024, 8:00 AM EDT - 10 months ago

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

Aug 8, 2024, 4:21 PM EDT - 1 year ago

While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market

Aug 7, 2024, 11:23 AM EDT - 1 year ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

Jul 24, 2024, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

Jun 13, 2024, 7:28 PM EDT - 1 year ago

Madrigal Pharma CEO talks competition in the GLP-1 space and new drug rollouts

Jun 12, 2024, 10:16 AM EDT - 1 year ago

Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked

Jun 6, 2024, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

May 7, 2024, 11:24 AM EDT - 1 year ago

Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript

May 7, 2024, 7:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Apr 30, 2024, 4:30 PM EDT - 1 year ago

Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label

mdalinaqvi Jul. 16 at 10:40 PM

$MDGL

0 · Reply

scott52 Jul. 16 at 9:59 PM

$MDGL Bid this stock higher so they can partner with Viking. Fuck Big Pharma.

0 · Reply

dllydalley29 Jul. 16 at 9:02 PM

$MDGL Need to get these spammers out of here.

0 · Reply

All_just_a_game Jul. 16 at 8:43 PM

$AKRO $ALT $MDGL $VKTX lmfao 😂 The bitch in class ALT drug can’t get a partner.

1 · Reply

balzofsteel Jul. 16 at 8:17 PM

0 · Reply

Wallst45 Jul. 16 at 8:08 PM

$MDGL OPPENHEIMER RAISED ITS PRICE TARGET ON MADRIGAL PHARMACEUTICALS TO $500

0 · Reply

balzofsteel Jul. 16 at 8:05 PM

$MDGL what will the shorts come up with next? MDGL going to $0? Try $500 What a bunch or sore losers!

0 · Reply

jeffshow12 Jul. 16 at 7:45 PM

0 · Reply

Wallst45 Jul. 16 at 7:25 PM

$MDGL BMY or PFE

0 · Reply

balzofsteel Jul. 16 at 7:18 PM

$MDGL 2044

0 · Reply

balzofsteel Jul. 16 at 7:13 PM

$MDGL Merck struck a $10 billion deal with Veron Pharmaceutical. SMMT in talks with AZN for its lung cancer drug . MDGL in talks with ?

0 · Reply

Thepatientone Jul. 16 at 7:06 PM

$ALT BIC vs $AKRO, $MDGL, $VKTX - The agonists are the platform of the future..

1 · Reply

Thepatientone Jul. 16 at 6:54 PM

$ALT BIC vs $AKRO, $MDGL, $VKTX

2 · Reply

INEEDMONNEY Jul. 16 at 6:54 PM

$AKRO $ALT $MDGL $VKTX can someone help me out with this? Is a lower or high number for wight loss best? i know pemvi is for mash but if were talking about weight loss isnt retatrutide BIC? Im long ALT im just confused how this graph is saying its BIC

4 · Reply

Thepatientone Jul. 16 at 6:49 PM

$ALT BIC vs $AKRO, $MDGL, $VKTX

1 · Reply

GPTInsights Jul. 16 at 6:49 PM

$VKTX $ALT $AKRO $MDGL No you just spam arbitrary old information and claim best in class but you don't know what you are talking about. There is a reason ALT has been trending down for a decade and got cut in half on results and GS gave it a $1 PT.

1 · Reply

Thepatientone Jul. 16 at 6:46 PM

$ALT BIC vs $AKRO, $MDGL, $VKTX

0 · Reply

Thepatientone Jul. 16 at 6:42 PM

$ALT BIC vs $AKRO, $MDGL, $VKTX in Obesity Only facts, do not lie. Do your DD.

1 · Reply

Tradinggraces17 Jul. 16 at 6:41 PM

$VKTX $ALT @Thepatientone but you said there’s no more drops for ALT. 🤣😂 Stop cross posting. No one cares. $AKRO $MDGL

0 · Reply

Thepatientone Jul. 16 at 6:35 PM

$ALT BIC VS $AKRO, $MDGL, and lets include $VKTX too. lol We provide facts, not lies...

1 · Reply

GPTInsights Jul. 16 at 6:20 PM

$ALT worst in class vs $AKRO, $MDGL and $VKTX - $1 GS price target and massive further dilution incoming. Do your DD.

4 · Reply

Wallst45 Jul. 16 at 6:10 PM

$MDGL 1.1 Million Volume 5X volumes already 🔥🔥🔥

0 · Reply

Market Cap	7.10B
Revenue (ttm)	180.13M
Net Income (ttm)	-465.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-258.64%
Debt to Equity Ratio	0.17

Volume	1,301,500
Avg Vol	308,010
Day's Range	N/A - N/A
Shares Out	22.20M
Stochastic %K	62%
Beta	-1.05
Analysts	Strong Sell
Price Target	$423.07